natgillin/translations-raw huggingface dataset:
400 mg to be taken as 4 tablets of 100 mg or 1 tablet of 400 mg once a day
400 mg vzamete kot 4 tablete po 100 mg ali 1 tableto po 400 mg enkrat na dan,
400 mg to be taken as 4 tablets once a day,
400 mg vzamete kot 4 tablete enkrat na dan
400 mg to be taken as 4 tablets once a day,
400 mg vzamete kot 4 tablete enkrat na dan,
400 mg to be taken as 8 capsules once a day.
400 mg vzamete kot 8 kapsul enkrat na dan,
400 mg to be taken as one tablet once a day,
400 mg vzamete kot eno tableto enkrat na dan
400 mg twice a day
400 mg dvakrat na dan
400 mg twice daily
400 mg dvakrat
400 mg twice daily
Placebo +
400 mg twice daily + OBT (N = 462)
dvakrat na dan + OBT (N = 462)
400 mg twice daily in patients with chronic or accelerated phase CML with resistance or intolerance to prior therapy.
400 mg dvakrat dnevno pri bolnikih s kronično ali pospešeno fazo KML z rezistenco na predhodno zdravilo ali z neprenašanjem predhodnega zdravila.
400 mg vial has a shelf life of 2 years.
Rok uporabnosti 400 mg viale 2 leti.
400 mg VIAL LABEL
400 mg NALEPKA VIALE
400 mg with 100 mg of ritonavir; doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded (see section 4.4).
Odmerkov zaviralcev protonske črpalke, ki so primerljivi z 20 mg omeprazola, se ne sme preseči (glejte poglavje 4.4).
400 mg/100 mg twice daily
lopinavir/ritonavir 400 mg/100 mg dvakrat dnevno
400 mg/400 mg (i.e.
Rifabutin, 150 mg
400 mg/m2 intravenous
400 mg/m2 intravensko bolus, sledi 600 mg/m2
400 mg/m2 intravenous bolus, followed by
400 mg/m2 intravensko bolus, sledi 600 mg/m2
400 mg/m2/daily, subsequently increased to 520 mg/m2/daily.
400 mg/m2/dan, kasneje pa zvečan odmerek 520 mg/m2/dan.
400 microgram
400 mikrogramov
400 micrograms fentanyl (as citrate)
400 mikrogramov fentanila (v obliki citrata)
400 micrograms of Bretaris Genuair corresponds to the amount of aclidinium bromide contained in the inhaler which delivers 322 micrograms of aclidinium.
400 mikrogramov zdravila Bretaris Genuair ustreza količini aklinidijevega bromida, ki ga vsebuje inhalator, ki dovede 322 mikrogramov aklidinija.
400 micrograms of Eklira Genuair corresponds to the amount of aclidinium bromide contained in the inhaler which delivers 322 micrograms of aclidinium.
400 mikrogramov zdravila Eklira Genuair ustreza količini aklinidijevega bromida, ki ga vsebuje inhalator, ki dovede 322 mikrogramov aklidinija.
400 ml polyethylene or multilayer plastic bags of solvent.
400 ml polietilenske ali večslojne plastične vrečke vehikla
400 mL white HDPE bottle containing 250 capsules with one 2-in-1 desiccant cylinder and two oxygen absorber cylinders, with a child resistant polypropylene closure.
400 ml bela plastenka iz polietilena visoke gostote, ki vsebuje 250 kapsul, skupaj z enim sušilnim valjčkom 2 v 1 in dvema valjčkoma za absorpcijo kisika, ter ima polipropilenski zamašek, varen za otroke.
400 pigs with an average bodyweight of 50 kg).
400 prašičev s povprečno telesno težo 50 kg).
400 Shire Way, Lexington, Massachusetts 02421 USA
400 Shire Way, Lexington, Massachusetts 02421 Združene države Amerike
400 U
400 enot
400 units
400 kosov
400 µg / spray
400 µg / odmerek pršila
400/100 mg BID
400/100 mg 2-krat na dan
400/100 mg BID)
(1400 mg dvakrat na dan)
400/100 mg BID)
400/100 mg dvakrat na
400/100 mg BID,
400/100 mg dvakrat na
400/100 mg BID,
Priporočeno
400/100 mg QD
atazanavir/r 300/100 mg:
400/100 mg twice daily
400/100 mg dvakrat na
400/100 mg twice daily).
400 mg/100 mg dvakrat na dan).
400/100 mg twice daily).
400/100 mg dvakrat na dan).
400/100 mg twice daily1
400/100 mg dvakrat na dan1
4000 (5 x 20 cartridges x 40) tablets (multipack)
4000 (5 x 20 vložki x 40) tablet (skupno pakiranje)
4000 IU
4000 i.e.
4000 IU/0.4 ml
4000 i.e./0,4 ml
4000 IU/0.5 ml
4000 i.e./0,5 ml
40000 IU/1.0 ml
40000 i.e./1,0 ml
400g sachet – 2 years.
400 g vrečka - 2 leti
402 cases
402 primerov
4020 Linz Austria
A-4020 Linz Avstrija
4042 Debrecen Hungary
Debrecen H-4042 Madžarska
4042 Debrecen Hungary
Pallagi út 13 4042 Debrecen Madžarska
4042 Debrecen,
4042 Debrecen, Madžarska
4042 Debrecen, Hungary
4042 Debrecen Madžarska
4042 Debrecen, Hungary
4042 Debrecen, Madžarska
40549 Düsseldorf Germany
40549 Düsseldorf Nemčija
4056 Basel Switzerland
4056 Basel Švica
406 patients who received docetaxel in combination with cisplatin.
406 bolnikih, ki so dobivali docetaksel v kombinaciji s cisplatinom;
406 patients who received docetaxel in combination with cisplatin.
406 bolnikih, ki so prejemali docetaksel v kombinaciji s cisplatinom.
40–49 3.3 mg* zoledronic acid
40–49 3,3 mg* zoledronske kisline
41 (13)b
CR+nCR+PR
41 (13)b
nCR n(%)
41 (4.7)
občasni
41 Chalton Street London, NW1 1JD United Kingdom
41 Chalton Street London, NW1 1JD Velika Britanija
41% received bisphosphonates.
41 % je prejemalo difosfonate;
41%a (28%, 52%)
41% a (28%, 52%)
41%c (23%, 55%)
41% c (23%, 55%)
41.5-49.4 kg
41,5-49,4 kg največji odmerek
41.7 (32.6 to 51.6)
41,7 (32,6-51,6)
41.8 to 45.4
41,8 do 45,4
410 389 359 337 305 275 213 139 73 29 3 0
410 389 359 337 305 275 213 139 73 29 3 0 everolimus
410 units*.
410 enot*.
42 ampoules
42 ampul
42 ampoules with 1 ml.
42 ampul z 1 ml
42 ampoules.
42 ampul.
42 chewable tablets
42 žvečljivih tablet
42 film-coated tablets
42 filmsko obloženih tablet.
42 film-coated tablets Xarelto 15 mg and 7 film-coated tablets Xarelto 20 mg.
42 filmsko obloženih tablet zdravila Xarelto po 15 mg in 7 filmsko obloženih tablet zdravila Xarelto po 20 mg.
42 hard capsules
42 kapsul
42 IU/kg)
42 i.e./kg)
42 IU/kg)
ggjandi inndæling,
42 months after completion of the full vaccination course, 100% and 99.4% of initially seronegative women remained seropositive for anti-HPV-16 and anti-HPV-18 antibodies, respectively.
42 mesecev po koncu celotnega cepljenja) ugotovili še prisotno seropozitivnost za protitelesa anti-HPV-16 pri 100 % in za anti-HPV-18 pri 99,4 %.
42 pipettes
42 merilnih kapalk
42 sachets
42 vrečk
42 single-use vials
42 vial za enkratno uporabo
42 tablets
14 tablet
42 tablets
42 tableti
42 tablets
EU/1/12/815/004
42 tablets: two transparent calendar blisters of 21 tablets each.
42 tablet: dva prozorna, z dnevi označena pretisna omota po 21 tablet.
42 transdermal patches
42 transdermalnih obližev
42 transdermal patches.
42 transdermalnih obližev
42% of patients did not receive prior docetaxel because they were deemed ineligible or refused to receive docetaxel.
42 % bolnikov predhodno ni prejelo docetaksela, saj so bili obravnavani kot neprimerni ali pa so prejemanje docetaksela zavrnili;
42%b (11%, 62%)
42 %b (11 %, 62 %)
42%b (21%, 57%)
42% b (21%, 57%)
42) tablets, 980 (10 packs of 98) tablets or 1000 (20 packs of 50) tablets.
Večktatno pakiranje vsebuje 840 (20 x42) tablet, 980 (10 x 98) tablet ali 1000 (20 x 50) tablet.
42.0 micrograms
42,0 mikrogramov
42.3 mg pyriproxyfen
42.3 mg piriproksifen
42.9% and 10.4% of patients in the BR-CAP arm were in the range 65-74 years and ≥ 75 years of age, respectively.
V skupini BR-CAP je bilo 42,9% bolnikov starih 65-74 let in 10,4% bolnikov, starih ≥ 75 let.
42.9% and 10.4% of patients in the BzmbR-CAP arm were in the range 65-74 years and ≥ 75 years of age, respectively.
V skupini BzmbR-CAP je bilo 42,9 % bolnikov starih 65-74 let in 10,4 % bolnikov starih ≥ 75 let.
420 mg QM
420 mg
420 mg QM (N=599)
420 mg 1-krat/mes ec (N = 599)
425 medical patients who are at risk for thromboembolic complications treated up to 14 days
425 internističnih bolnikih s tveganjem trombemboličnih zapletov, zdravljenih do 14 dni dolgo.
426 patients aged 75 years or older.
426 bolnikih, starih 75 let ali več.
43 (40.2)
Povprečna izhodiščna
43 IU/kg)
(30;
43 mcg
43 μg
43 mcg
za inhaliranje
43 subjects, 62.8% versus 13 out of 43 patients, 30.2%, p=0.002).
43 preiskovancev, 62,8 %, v primerjavi s 13 od 43 preiskovancev, 30,2 %; p = 0,002).
43% versus placebo
43 % v primerjavi s placebom
43.0% vs 32.2%
43,0 % v prim. z
43.1 mo (35.3, 48.3)
(35,3; 48,3)
43.1 mo(35.3, 48.3)
43,1 mesecev (35,3; 48,3)
43.2b
43,2
43.3% vs 29.2%
43,3 % v prim. s
43122 Parma
43122 Parma Italija
437.5 mg (5.5 ml) twice daily
437,5 mg (5,5 ml) dvakrat na dan
44 micrograms (12 million IU)/0.5 mL
44 mikrogramov (12 milijonov i.e.)/0,5 ml
44 micrograms tiw
44 mikrogramov trikrat/teden
44 micrograms, then ‘initiation/titration’, press ‘change’, select ‘on’, press ‘ok’ and confirm ‘initiation/titration on’ by pressing ‘ok’.
44 mikrogramov, nato "začetek/titriranje", nato pritisnite "spremeni", izberite "vklop", pritisnite "ok" in potrdite "začetek/vklop titriranja" s pritiskom na "ok".
44 patients with schizophrenia > 65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
Pri 44 bolnikih s shizofrenijo, starejših od 65 let, odmerjanje od 5 do 20 mg/dan ni bilo povezano s kakim razločevalnim profilom neželenih učinkov.
44 patients with schizophrenia  65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
44 bolnikih s shizofrenijo, starejših od 65 let, odmerjanje od 5 do 20 mg/dan ni bilo povezano s kakim razločevalnim profilom neželenih učinkov.
44 single-use 1 ml ampoules of solvent
44 1-ml ampul vehikla za enkratno uporabo
44 µg (12 million IU)
44 mikrogramov (12 milijonov i.e.)
44.1%
karbamazepin
44.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo had a 50 % or greater reduction from baseline in the partial onset seizure frequency per week.
Pri 44,6 % bolnikov, ki so se zdravili z levetiracetamom, in 19,6 % bolnikov, ki so prejemali placebo, je bilo 50 ali več odstotno zmanjšanje pogostnosti napadov parcialnega izvora na teden.
44.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo had a 50 % or greater reduction from baseline in the partial onset seizure frequency per week.
Pri 44,6 % bolnikov, ki so se zdravili z levetiracetamom, in 19,6 % bolnikov, ki so prejemali placebo, je bilo 50- ali več odstotno zmanjšanje pogostnosti napadov parcialnega izvora na teden.
448 (4 x 112) capsules
448 (4 x
448 (8 x 56) capsules and 10 inhalers (2 x monthly multipack wrapped in foil) Not all pack sizes may be marketed.
448 (8 x 56) kapsul in 10 inhalatorjev (2 x mesečno pakiranje, zavito v folijo) Na trgu morda ni vseh navedenih pakiranj.
448 (8x 56) capsules
448 (8x 56) kapsul
448 capsules (4 bottles of 112 capsules)
448 kapsul (4 plastenke po 112 kapsul)
45 (41)
p-vrednosta
45 cm Flexible Tip
Prožni nastavek dolžine 45 cm
45 kg < calves < 60 kg: 12 ml of HALOCUR once a day during 7 consecutive days
45 kg < teleta < 60 kg: 12 ml zdravila HALOCUR, 1-krat na dan, 7 zaporednih dni
45 kg < calves < 60 kg: 12 ml of HALOCUR once a day for 7 consecutive days
45 kg < teleta < 60 kg: 12 ml zdravila HALOCUR, 1-krat na dan, 7 zaporednih dni
45 mg 13C-
45 mg 13C sečnine
45 mg oseltamivir suspension delivers 1.3 g of sorbitol.
45 mg suspenzije oseltamivir vsebuje 1,3 g sorbitola.
45 mg tablet: blue, square (6.8 mm on a side, major axis 8.2 mm), shallow-convex, debossed with “OTSUKA” and “45” on one side
15-mg tableta: modra, trikotna (večja os: 6,58 mm, manjša os: 6,20 mm), plitko konveksna z vtisnjenim napisom "OTSUKA" in "15" na eni strani.
45 mg tablet: blue, square, with “OTSUKA” and “45” on one side
45-mg tableta: modra, kvadratna z vtisnjenim napisom "OTSUKA" in "45" na eni strani.
45 mg/0.5 mL
45 (56%)a
45 mg/kg/day group on either day 14 or day 15 of gestation.
14. ali 15. dne brejosti opazili rdeč izcedek iz nožnice.
45 minutes in adults and 1-4 hours in paediatric patients via gravity feed, a syringe-type pump, or an infusion pump.
45 minut pri odraslih in 1-4 ure pri pediatričnih bolnikih, s pomočjo kapalnega sistema, brizgalne črpalke ali infuzijske črpalke.
45 ml/day
45 ml/dan
45 ml/min/1.73 m2 or CrCl persistently below 45 ml/min.
45 ml/min/1,73 m2 ali pri katerih CrCl trajno pade pod 45 ml/min.
45 Place Abel Gance 92100 BOULOGNE FRANCE
45 Place Abel Gance 92100 BOULOGNE FRANCIJA
45 to ≤ 65 years of age
Starost od 45 do ≤ 65 let
45% patient had died and OS is therefore considered immature.
28. oktobra 2015; približno 45 % bolnikov je umrlo in zato oceno celokupnega preživetja ocenjujemo kot nezrelo.
45%d (6%, 68%)
45 %d (6 %, 68 %)
45, 51, 76, 74 and 80 New York Avenue, Framingham, MA 01701, USA Genzyme Flanders bvba, Cipalstraat 8, 2440 Geel, Belgium
45, 51, 74, 76 and 80 New York Avenue, Framingham, MA 01701, ZDA Genzyme Flanders bvba, Cipalstraat 8, 2440 Geel, Belgija
45,51, 68, 74,76 and 80 New York Avenue
45,51,68,74,76 and 80 New York Avenue Framingham,
45.4
vrednost p
45.5 to 49.0
45,5 do 49,0
45.5b
45,5
45.8% (n=60)
45,8 % (n = 60)
450 - 600 mg/kg/day in children weighing less than 20 kg
450 – 600 mg/kg/dan pri otrocih, ki tehtajo manj kot 20 kg
450 - 600 mg/kg/day in neonates, infants and children weighing less than 20 kg
450 – 600 mg/kg/dan pri novorojenčkih, dojenčkih in otrocih, ki tehtajo manj kot 20 kg
450 - 600 mg/kg/day in neonates, infants and children weighing less than 20 kg
450–600 mg/kg/dan pri novorojenčkih, dojenčkih in otrocih, ki tehtajo manj kot 20 kg,
450 IU (33 g)/vial
450 i.e. (33 μg)
450 IU/0.75 ml (33 micrograms/
napolnjenem
450 mg (4.5 ml) twice daily
450 mg (4,5 ml) dvakrat na dan
450 mg (4.5 ml)twice daily
450 mg (4,5 ml) dvakrat na dan
450 mg PREZISTA/60 mg ritonavir twice daily
450 mg PREZISTA/60 mg ritonavir a dvakrat na dan
450 milligram PREZISTA + 60 milligram ritonavir twice a day
450 miligramov zdravila PREZISTA + 60 miligramov ritonavirja dvakrat na dan
4500 IU
4500 i.e.
45520 Gidy France
45520 Gidy Francija
45520 Gidy – France
45520 Gidy – Francija
45731 Waltrop Germany
45731 Waltrop Nemčija
46
tedni
46 b
0,4 b
46 b
47 b
46 days
46 dni
46 Galli Drive, Novato, CA 94949 United States of America
46 Galli Drive, Novato, CA 94949 Združene države Amerike
46 patients continued with octreotide intramuscular use treatment.
46 bolnikov pa je nadaljevalo zdravljenje z oktreotidom za intramuskularno uporabo.
46%
N=96
46% and 38%, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit.
Pri končnem obisku je 46 % oziroma 38 % bolnikov bilo stabilnih pri zdravljenju s febuksostat 80 mg oziroma 120 mg na dan, in se popolna umiritev primarno tipljivega tofa.
46% of patients had no pain or WHO scale 1 (asymptomatic or mildly symptomatic) and 54% had pain WHO scale 2-3.
46 % bolnikov ni imelo bolečin ali je imelo bolečine stopnje 1 po lestvici SZO (asimptomatske ali blago simptomatske) in 54 % jih je imelo bolečine stopnje 2 - 3 po lestvici SZO;
460
DOE
460 milligram (4.6 milliliter)
460 miligramov (4,6 mililitra)
47 b
12
47 b
57 b
47 out of 56 MIs in the eptifibatide group).
92 miokardnih infarktov v skupini placebo in 47 od 56 miokardnih infarktov v skupini za eptifibatid).
47% (43) (p=0.001b)
47 % (43) (p = 0,001b)
47.3 (32-ne)
47.3 (32,0–no)
47.3%), p<0.001.
47,3 %), p < 0,001.
47.6 months (37.8 months)
47,6 meseca (37,8 mesecev)
47014 Meldola (FO) Italy
47014 Meldola (FO) Italija
4716 patients were treated with percutaneous coronary angioplasty with administration of anticoagulant following the rules for masking investigational medicinal product.
Pri 4.716 bolnikih so opravili perkutano koronarno angioplastiko ob sočasnem dajanju antikoagulanta, po tem ko so izvedli slepljenje preiskovanega zdravila.
4716 patients were treated with percutaneous coronary angioplasty with administration of anticoagulant following the rules for masking investigational medicinal product.
Pri 4.716 bolnikih so opravili perkutano koronarno angioplastiko ob sočasnem dajanju antikoagulanta, potem ko so izvedli slepljenje preiskovanega zdravila.
4745-457 S. Mamede do Coronado - Portugal tel: +351 22 986 61 00
4745-457 S. Mamede do Coronado - Portugalska tel: +351 22 986 61 00
478 of the enrolled patients (32%) were defined as having a severe disease (CDAI score > 300 and concomitant corticosteroid and/or immunosuppressants) corresponding to the population defined in the indication (see section 4.1).
Pri 478 zajetih bolnikih (32%) je bila bolezen opredeljena kot huda (seštevek CDAI > 300 ter sočasno zdravljenje s kortikosteroidom in/ali imunosupresivom), kar ustreza populaciji, opredeljeni pri indikacijah (glejte poglavje 4.1).
48 alcohol swabs
24 adapterjev za viale 48 alkoholnih blazinic
48 applicators
48 aplikatorjev
48 capsules
48 kapsul
48 MIU (480 µg/0.8
48 MIU (480 µg/0,8
48 MIU (480 µg/0.8 ml)
48 MIU (480 µg/0,8 ml)
48 MU (480 µg/0.5 ml)
48 ME (480
48 MU (480 µg/0.5 ml)
µg/0,2 ml)
48 MU (96 MU/ml)
(96 ME/ml)
48 MU/0.5 ml
48 M e./0,5 ml
48 tablets.
48 tablet
48 weeks with pegylated interferon alfa-2b and ribavirin, growth inhibition is observed, the reversibility of which is uncertain (see section 4.4).
V času kombinirane terapije s pegiliranim interferonom alfa-2b in ribavirinom, ki je trajala do 48 tednov, so opazili tudi zastoj rasti, katerega reverzibilnost ni gotova (glejte poglavje 4.4).
48-months 74
mesecev 74
48-week active comparator controlled study
48-tedenska študija, kontrolirana z aktivnim primerjalnim zdravilom
48-week study no unexpected safety findings were observed in either dosing group.
V tej 48-tedenski raziskavi v nobeni od skupin z različnim odmerjanjem niso poročali o nepričakovanih izsledkih, povezanih z varnostjo.
48.0)
N/A
48.3 (46.4 to 58.3)
48,3 (46,4-58.3)
48.4 months (NR)
48,4 meseca (NR)
48.5 months
48,5 meseca
48.7 microgram/kg/day was identified as ‘no observed adverse effect level’ (NOAEL).
48,7 mikrogramov/kg/dan opredeljen kot »stopnja brez opaznih neželenih učinkov« (no observed adverse event level - NOAEL).
48.7% of patients reached the HbA1c target of <7% without confirmed hypoglycaemic episodes, which was a significantly higher proportion than observed with insulin degludec (15.6%, odds ratio 5.57, p<0.0001).
Ciljno vrednost HbA1c < 7 % je doseglo 48,7 % bolnikov brez potrjenih hipoglikemij, kar je pomembno večji delež od deleža pri uporabi insulina degludek (15,6 %, razmerje obetov 5,57, p<0,0001).
48.8
(min-maks)
480 tablets
480 tablet
48159 Münster Germany
48159 Münster Nemčija
48159 Münster Germany
DE-48159 Münster Nemčija
483 mg/g
(Izmišljeno
4866 Austria
4866 Avstrija
49 %.
49 % bolnikov.
49 a
54 a
49 IU/kg)
49 a.e./kg
49 mg (0.5 ml)twice daily
49 mg (0,5 ml) dvakrat na dan
49 mg (0.5 ml)twice daily
49 mg (0.5 ml) dvakrat na dan
49 patients received subcutaneous injections of Zutectra of 500 IU (1 mL) or 1,000 IU (2 mL) (dose adaptation in exceptional cases up to 1,500 IU) per week or fortnightly according to serum anti-HBs trough levels.
49 bolnikov je dobilo podkožne injekcije zdravila Zutectra 500 i.e. (1 ml) ali 1.000 i.e. (2 ml) (prilagoditev odmerka v izjemnih primerih do 1.500 i.e.) na teden ali vsaka dva tedna, glede na najnižje ravni protiteles anti-HBs.
49 tablets
49 tablet
49 x 1 film-coated tablets.
49 x 1 filmsko obloženih tablet.
49 x 1 orodispersible tablets
49 x 1 orodisperzibilna tableta
49 x 1 tablet (unit dose)
49 x 1 tableta (enkratni odmerek)
49 x 1 tablets
49 tablet
49 x 1 tablets
49 x 1 tablet
49 x 1 tablets
49 x 1 tableta (za enkratni odmerek)
49%b
32,3
49.1 to 52.6
49,1 do 52,6
49.4 microgram per mL in week 36.
49,4 mikrograma/ml v 36. tednu.
49.5-58.4 kg
49,5-58,4 kg največji odmerek
490 ml
raztopina
492 cells/mm3 (7.8 %)
492 celic/mm3 (7,8 %)
4: Clear cap
4: prozorni pokrovček
4a D-33602 Bielefeld Germany
4a D-33602 Bielefeld Nemčija
4a recommendation: Gently squeeze the applicator and apply the veterinary medicinal product to the skin along the dog's back, beginning between the shoulder blades, in the number of spots and order shown in the diagrams below and squeezing until the applicator is empty.
4a priporočila: Rahlo stisnite kapalko in nanesite zdravilo na kožo vzdolž hrbta, pričnite med lopaticama in zdravilo nanesite na več mest kot kaže diagram spodaj, kapalko stiskajte dokler ni prazna.
4a recommendation: Gently squeeze the applicator and apply the veterinary medicine to the skin along the dog's back, beginning between the shoulder blades, in the number of spots and order shown in the diagrams below and squeezing until the applicator is empty.
4a priporočila: Rahlo stisnite kapalko in nanesite zdravilo na kožo vzdolž hrbta, pričnite med lopaticama in zdravilo nanesite na več mest kot kaže diagram spodaj, kapalko stiskajte dokler ni prazna.
4a, 33602 Bielefeld, GERMANY
4a, 33602 Bielefeld, NEMČIJA
4b recommendation: Regardless of the dog’s body weight, using the applicator tip, part the hair at the base of the tail and begin applying the veterinary medicinal product directly onto the skin in a continuous line from the base of the tail along the centre of the back all the way up to the shoulder blades, as shown in the diagram, squeezing the applicator until it is empty.
4b priporočila: Ne glede na telesno težo psa, s pomočjo konice kapalke, razmaknite dlako na bazi repa in začnite nanašati zdravilo na kožo v neprekinjeni liniji od baze repa, preko centra hrbta do lopatic, kot je prikazano v diagramu, kapalko stiskajte dokler ni prazna.
4b recommendation: Regardless of the dog’s body weight, using the applicator tip, part the hair at the base of the tail and begin applying the veterinary medicine directly onto the skin in a continuous line from the base of the tail along the centre of the back all the way up to the shoulder blades, as shown in the diagram, squeezing the applicator until it is empty.
4b priporočila: Ne glede na telesno težo psa, s pomočjo konice kapalke, razmaknite dlako na bazi repa in začnite nanašati zdravilo na kožo v neprekinjeni liniji od baze repa, preko centra hrbta do lopatic, kot je prikazano v diagramu, kapalko stiskajte dokler ni prazna.
4Children < 5 years of age.
4Otroci, mlajši od 5 let.
4Duration of response: interval from the onset of response to disease progression.
3trajanje odgovora: interval od nastopa odgovora do progresije bolezni
4In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin.
4 V kontroliranih kliničnih preskušanjih je bila incidenca poročil o srčnem popuščanju ob zdravljenju s pioglitazonom enaka kot v skupinah zdravljenja s placebom, metforminom in sulfonilsečnino, vendar je bila povečana pri uporabi kombiniranega zdravljenju z insulinom.
4L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from the insect Trichoplusia ni.
4L1 protein v obliki nekužnih virusu podobnih delcev (VLPs, “virus-like particles”), pridobljenih s tehnologijo rekombinantne DNA s pomočjo bakulovirusnega ekspresijskega sistema na osnovi Hi-5 Rix4446 celic, pridobljenih iz žuželke Trichoplusia ni.
4L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from Trichoplusia ni.
4L1 protein v obliki nekužnih virusu podobnih delcev (VLPs, “virus-like particles”), pridobljenih s tehnologijo rekombinantne DNA s pomočjo bakulovirusnega ekspresijskega sistema na osnovi Hi- 5 Rix4446 celic, pridobljenih iz Trichoplusia ni.
4October 1995 to April 30, 1998
4Od oktobra 1995 do 30. aprila 1998
4Q2017
4. četrtletje 2017
4th appearance
4. pojav
4th occurrence
4. pojav
4th week
4. teden
4the dosing of insulin glargine was open­labelled and was applied according to Guideline for titration of insulin glargine.
4Odmerek insulina glargin je bil znan (odprta študija), odmerjanje pa je potekalo v skladu s smernicami za prilagajanje odmerka insulina glargin.
4W CQR
4W-CQR
4x1 film-coated tablets 30x1 film-coated tablets 100x1 film-coated tablets
4x1 filmsko obloženih tablet 30x1 filmsko obloženih tablet 100x1 filmsko obloženih tablet.
5 % dextrose and 0.45 % sodium chloride 5 % dextrose and 0.9 % sodium chloride 5 % dextrose and 20 mEq KCl
5 % glukoza in 0,45 % natrijev klorid 5 % glukoza in 0,9 % natrijev klorid 5 % glukoza in 20 mEq KCl
5 % dextrose with Lactated Ringer’s solution
5 % glukozo z raztopino Ringerjevega laktata
5 (2)b
121 (38)b
5 (5 x 1) bag (multipack)
5 vreč (5X1)
5 (5 x 1) bottle (multipack)
5 plastenk (5X1)
5 (5 x 1) vial (multipack)
5 (5 x 1) viala (večje pakiranje)